Vanguard Group Inc. Reduces Holdings in Lantheus Holdings, Inc. $LNTH

Vanguard Group Inc. decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,699,381 shares of the medical equipment provider’s stock after selling 253,037 shares during the quarter. Vanguard Group Inc. owned approximately 0.10% of Lantheus worth $445,844,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LNTH. Blue Trust Inc. raised its stake in Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 230 shares during the period. United Community Bank boosted its position in Lantheus by 15.6% during the third quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 245 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 275 shares in the last quarter. Concurrent Investment Advisors LLC increased its stake in shares of Lantheus by 10.3% in the third quarter. Concurrent Investment Advisors LLC now owns 3,936 shares of the medical equipment provider’s stock worth $202,000 after purchasing an additional 366 shares in the last quarter. Finally, Orion Porfolio Solutions LLC raised its position in shares of Lantheus by 3.9% in the second quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock valued at $819,000 after purchasing an additional 377 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $85.82 on Wednesday. The company has a 50 day moving average of $79.09 and a 200 day moving average of $68.41. The stock has a market cap of $5.59 billion, a P/E ratio of 25.47 and a beta of -0.08. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $108.90. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on LNTH. Truist Financial raised their price objective on shares of Lantheus from $89.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. William Blair reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a report on Friday. Finally, Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $88.86.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.